Our client was a US-based clinical stage biotech company developing a reformulation of a well-established orphan drug targeting a range of indications in neuro-endocrinology.
Client leadership requested DRG to validate key assumptions on the revenue forecast of the drug in its lead indication and provide guidance on the go-to-market model and associated costs in order to inform a go/no go decision on launch of the drug in Europe.
The client needed to understand:
- The size of the addressable patient population given epidemiology and the evolution of treatment landscape
- Pricing and access expectations, and potential price/access trade-offs
- Uptake and peak preference share given the current and future competitive landscape
- Medical, access and commercial resources required for a successful launch